MergerLinks - Natalie Garland-Collins

PrivateMajorityAcquisition

target

Expedeon (proteomics And Immunology Business)

bidder

Abcam

£103m

16 dealmakers

AcquisitionPrivate EquityPrivate

target

Achilles Therapeutics

bidder

Syncona

£100m

8 dealmakers

MinorityAcquisitionPrivatePrivate Equity

target

Azeria Therapeutics

bidder

Sixth Element Capital

£32m

7 dealmakers

AcquisitionPrivateMajority

target

Marker Gene Technologies

bidder

Abcam

value n/a

6 dealmakers

PublicVenture CapitalPrivate EquityAcquisitionMinorityDomestic

Pharmaceuticals

target

Abcam

bidder

Durable Capital Partners

£110m

4 dealmakers

AcquisitionPrivateMajorityCross Border

target

BIOVISION

bidder

Abcam

£244m

20 dealmakers

Cross BorderAcquisitionMajorityPrivate

Health Care Facilities

target

Gyroscope Therapeutics

bidder

Novartis

£1,132m

20 dealmakers

MinorityPrivatePrivate EquityVenture CapitalAcquisitionCross Border

target

Evox Therapeutics

bidder

Orbimed Advisors

£69m

10 dealmakers

Private EquityCross BorderVenture CapitalAcquisitionPrivateMinority

Medical Equipment

target

Omass Therapeutics

bidder

Oxford University Clinic

£75m

13 dealmakers

PrivateMinorityPrivate EquityDomesticVenture CapitalAcquisition

target

Swanbio Therapeutics

bidder

Syncona

£45m

10 dealmakers

Cross BorderTender OfferMajorityAcquisitionPublic

target

Applied Genetic Technologies Corporation

bidder

Syncona

£64m

9 dealmakers

Netherlands

Private EquityCross BorderAcquisitionMajorityPrivate

target

Neogene Therapeutics

bidder

Astrazeneca

£264m

60 dealmakers

DomesticMinorityPrivateAcquisition

target

Quell Therapeutics

bidder

Astrazeneca

value n/a

6 dealmakers

Cross BorderMinorityPrivatePrivate EquityAcquisition

Health Care Services

target

Beacon Therapeutics

bidder

Syncona

£96m

8 dealmakers

AcquisitionDomesticMajorityPublicScheme

target

Freeline Therapeutics

bidder

Syncona

£11m

6 dealmakers